» Articles » PMID: 35223973

Surgery and Surgery Approach Affect Survival of Patients With Stage I-IIA Small-Cell Lung Cancer: A Study Based SEER Database by Propensity Score Matching Analysis

Overview
Journal Front Surg
Specialty General Surgery
Date 2022 Feb 28
PMID 35223973
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study was to observe the significance of surgery and its approach in stage I-IIA (according to 8th American Joint Committee on Cancer Staging Manual) small-cell lung cancer (SCLC) using the Surveillance, Epidemiology, and End Results (SEER) database.

Patients And Methods: A total of 1,421 patients from ages 31 to 93 years who were diagnosed with stage I-IIA SCLC in the SEER database from 2010 to 2015 were analyzed. The 1:1 propensity score matching analysis was used to minimize the effect of selection bias, and 355 pairs of patients' data was performed subsequent statistical analysis. K-M analysis and a Cox proportional hazards model were used to observe the role of surgery and other clinical features in the patients' prognoses on cancer-specific survival (CSS).

Results: Overall, within the whole cohort, the 3- and 5-year CSS rates were 41.0 and 34.0%, respectively. In a Cox regression that adjusted for other clinical features, patients were more likely to benefit from the surgery [hazard ratio (HR) 0.292, 95% confidence interval (CI) 0.237-0.361, < 0.001]. Unadjusted 5-year cancer-specific survival among those with surgery was 55.0%, compared with 23.0% among those without surgery. In the propensity scored-matched dataset, however, 5-year CSS among those with surgery was 54.0%, compared with 17.0% among those without surgery (HR 0.380, 95%CI 0.315-0.457, < 0.001). In patients who received surgery, cases with lobectomy had a better 5-year CSS than those without lobectomy (65.0 vs. 39.0%). The lobectomy might be a protective factor for patients who underwent resection in CSS (HR 0.433, 95%CI 0.310-0.604, < 0.001).

Conclusions: We suggested that the surgery and lobectomy were the independent prognostic as well as the protective factors in stage I-IIA SCLC patients. We recommended that patients with no surgical contraindications receive surgery, preferably, lobectomy.

Citing Articles

The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study.

Jiang H, Xie W, Li X, Wang H, Yu W, Chen X J Cardiothorac Surg. 2023; 18(1):216.

PMID: 37408065 PMC: 10324150. DOI: 10.1186/s13019-023-02314-1.


Excellent survival of pathological N0 small cell lung cancer patients following surgery.

Fu Z, Li D, Deng C, Zhang J, Bai J, Li Y Eur J Med Res. 2023; 28(1):91.

PMID: 36810128 PMC: 9942372. DOI: 10.1186/s40001-023-01044-3.


Advances in Intraoperative Flow Cytometry.

Figueiredo M, Alexiou G, Vartholomatos G, Rehder R Int J Mol Sci. 2022; 23(21).

PMID: 36362215 PMC: 9655491. DOI: 10.3390/ijms232113430.


Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues.

Brascia D, Marulli G Curr Treat Options Oncol. 2022; 23(12):1645-1663.

PMID: 36269459 PMC: 9768012. DOI: 10.1007/s11864-022-01026-3.


Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study.

Jin K, Liu X, Guo Y, Wu C, Dai J, Li J Transl Lung Cancer Res. 2022; 11(9):1951-1960.

PMID: 36248336 PMC: 9554686. DOI: 10.21037/tlcr-22-616.


References
1.
Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A . Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?. Cancer. 2010; 116(5):1350-7. DOI: 10.1002/cncr.24853. View

2.
Li Y, Hu S, Xie J, Zhang X, Zong Y, Xu B . Effects of surgery on survival of elderly patients with stage I small-cell lung cancer: analysis of the SEER database. J Cancer Res Clin Oncol. 2019; 145(9):2397-2404. DOI: 10.1007/s00432-019-02976-2. View

3.
Lim E, Belcher E, Yap Y, Nicholson A, Goldstraw P . The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol. 2008; 3(11):1267-71. DOI: 10.1097/JTO.0b013e318189a860. View

4.
Rudin C, Giaccone G, Ismaila N . Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Oncol Pract. 2018; 12(1):83-86. DOI: 10.1200/JOP.2015.008201. View

5.
Peng A, Li G, Xiong M, Xie S, Wang C . Role of surgery in patients with early stage small-cell lung cancer. Cancer Manag Res. 2019; 11:7089-7101. PMC: 6667680. DOI: 10.2147/CMAR.S202283. View